London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Five year follow-up of riboflavin/ultraviolet A (370nm) corneal collagen cross-linking to halt the progression of keratoconus

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Cross-Linking II

Session Date/Time: Tuesday 16/09/2014 | 16:30-18:00

Paper Time: 17:20

Venue: Boulevard A

First Author: : J.Alio del Barrio UK

Co Author(s): :    D. O'Brart   P. Patel   N. O'Brart   G. Lascaratos     

Abstract Details

Purpose:

To determine the long-term efficacy and safety of riboflavin/ultraviolet A corneal cross-linking (CXL) to halt the progression of Keratoconus.

Setting:

St. Thomas’ Hospital, London, United Kingdom.

Methods:

Thirty-five patients (35 eyes) who had undergone CXL with epithelial removal 5 or more years previously were examined.

Results:

At 5 years, mean spherical equivalent (SEQ) increased by +0.78 diopters (D) (p<0.001), mean Simulated K (Sim K) reduced by 0.86D (p<0.00001), Cone Apex Power (CAP) reduced by 1.1D (p<0.0002) and root mean square (RMS) (p<0.0001), coma (p<0.0001), and secondary astigmatism (p<0.001) decreased compared to preoperative values. Compared to values at 1 year, mean refractive cylinder reduced by 0.26D (p<0.05), mean Sim K reduced by 0.46D (p<0.0005), CAP reduced by 0.81D (p<0.01), RMS (p<0.001), coma (p<0.002) and secondary astigmatism (p<0.02) reduced and central pachymetry increased (p<0.05) at 5 years. No treated eyes showed evidence of progression at 5 years. None lost >1 line of CDVA. Eight untreated fellow eyes progressed during the follow-up period and underwent CXL.

Conclusions:

CXL is an effective treatment to halt the progression of keratoconus at 5 years, with no sight-threatening complications. Improvements in topographic and wave-front indices present at 1 year continue to improve at 5 years.

Financial Interest:

NONE

Back to previous